Supplemental Readings and References
837
advances in molecular biology and in recombinant protein
production methods can ultimately be expected to lead to
the elimination of AIDS and hepatitis as well as other viral
disease. Immune system recognition of transformed (can-
cerous) cells and discrimination between these and normal
cells makes it possible to envision immunological target-
ing of transformed cells using humanized monoclonal an-
tibodies and agents to selectively kill the cancer cells. Even
more existing is the possibility for the development of vac-
cines that promote formation of antibodies to cancer cells
and selective destruction of them by the immunological
mechanisms described in this chapter. As our knowledge
of immune response grows, the opportunities to prevent
disease expand. Engineering molecules that participate in
this system also provides opportunities for new therapeutic
drugs to combat the disease that have not been prevented.
Optimism regarding new immunotherapies is justified.
Acknowledgments
The images shown in this chapter were created using
RasMol 2.6, Molecular Graphics Visualisation Tool by
Roger Sayle, BioMolecular Structures Group, Glaxo
Research & Development, Greenford, Middlesex, UK.
The coordinates were obtained from the Protein Data
Bank at Brookhaven National Laboratory as described
in F. C. Bernstein, T. F. Koetzle, G. J. B. Williams,
E. F. Meyer, Jr., M. D. Brice, J. R. Rodgers, O. Kennard,
T. Shimanouchi, and M. Tasumi: “The Protein Data Bank:
A Computer-Based Archival File for Macromolecular
Structures.”
Mol. Biol.
112, 535-542 (1977).
Supplemental Readings and References
P. J. Delves and I. M. Roitt: The immune system, Part I.
N ew E n g la n d Jo u rn a l
o f M ed icin e
343, 37 (2000).
P. J. Delves and I. M. Roitt: The immune system, Part II.
N ew E n g la n d
J o u rn a l o f M ed ic in e
343, 108 (2000).
J. R. Gruen and S. M. Weissman: Evolving view of the major histocompat-
ibility complex.
B lo o d
90,4252 (1997).
J. Kuby:
Im m u n o lo g y,
W. H. Freeman, San Francisco, 1997, p. 664.
P-H. Lambert and C-A. Siegrist: Vaccines and vaccination.
B ritish M ed ic a l
J o u rn a l
315, 1595(1997).
A. D. Luster: Chemokines—chemotactic cytokines that mediate inflamma-
tion.
N e w E n g la n d J o u rn a l o f M ed icin e
338,436 (1998).
J. J. Oppenheim and M. Feldman:
C yto kin e R eferen ce.
Academic Press,
San Diego, 2000, p. 2000.
C. P. Price and D. J. Newman (eds.):
P rin cip les a n d P ra ctice o f Im m u n o a s-
sa y,
2nd Ed. Stockton Press, New York, 1997, p. 667.
I. M. Roitt:
E ssen tia l Im m u n o lo g y,
Blackwell Scientific Publications,
Oxford, 1997, p. 448.
B. J. Rollins: Chemokines.
B lo o d
90, 909 (1997).
P. Saikumar, Z. Dong, V. Mikhailov, et al.: Apoptosis: Definition, mecha-
nisms, and relevance to disease.
A m e rica n J o u rn a l o f M ed ic in e
107, 489
(1999).
M. Santos-Rosa, J. Bienvenu, and J. Whicher: Cytokines in
T ietz T extbook o f
C lin ica l C h em istry,
3rd ed. C. A. Burtis and E. R. Ashwood (Eds); W.B.
Saunders, Philadelphia, 1999, p. 541.
A. C. Ward, I. Touw, and A. Youshimura: The Jak-Stat pathway in normal
and perturbed hematopoiesis.
B lo o d
95, 19 (2000).
K. Whaley and W. Schwaeble: Complement and complement deficiencies.
S em in a rs in L iv e r D isea se
17, 297 (1997).
